Dimension Therapeutics Inc. (NASDAQ:DMTX) shares were up 4.4% on Thursday . The stock traded as high as $6.44 and last traded at $6.40, with a volume of 59,437 shares traded. The stock had previously closed at $6.13.

Several research analysts have recently weighed in on DMTX shares. Goldman Sachs Group Inc. downgraded shares of Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research report on Wednesday, March 30th. Zacks Investment Research downgraded shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 29th. Citigroup Inc. dropped their target price on shares of Dimension Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 29th. Canaccord Genuity reissued a “buy” rating on shares of Dimension Therapeutics in a research report on Saturday, May 14th. Finally, Jefferies Group assumed coverage on shares of Dimension Therapeutics in a research report on Thursday, June 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Dimension Therapeutics has an average rating of “Buy” and a consensus price target of $17.56.

The firm’s market capitalization is $160.14 million. The stock’s 50 day moving average price is $7.77 and its 200-day moving average price is $7.92.

Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Thursday, May 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.19. The business had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.24 million. On average, equities analysts predict that Dimension Therapeutics Inc. will post ($1.96) EPS for the current fiscal year.

In other Dimension Therapeutics news, SVP K. Reed Clark sold 5,000 shares of the company’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the senior vice president now directly owns 5,000 shares in the company, valued at approximately $50,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

An institutional investor recently bought a new position in Dimension Therapeutics stock. Jennison Associates LLC bought a new position in shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned about 2.97% of Dimension Therapeutics as of its most recent filing with the SEC.

Dimension Therapeutics, Inc is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A, hemophilia B and rare genetic diseases. The Company’s adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.